2026-01-28 · Source: PR Newswire Insurance
Summary in 3 Points • China Medical University Hospital, Ever Supreme Bio Technology, and Shine-On Biomedical achieve breakthrough in exosome-based drug delivery for Parkinson's treatment • The new method successfully delivers curcumin across the blood-brain barrier, a world-first in targeting brain diseases • This innovation could transform pharmaceutical risk assessments and underwriting in the London Market --- China Medical University Hospital (CMUH), in collaboration with **Ever Supreme Bio Technology** and **Shine-On Biomedical**, has announced a groundbreaking development in the treatment of **Parkinson's Disease**. Under the leadership of Superintendent Dr. Cho Der-Yang, the team has successfully created a world-first exosome-based drug delivery system that can transport **curcumin** across the **blood-brain barrier**. This innovative approach could significantly enhance the effectiveness of treatments for brain diseases, marking a pivotal advancement in medical technology. The announcement was made on January 28, 2026, highlighting the potential of this method to revolutionize how **neurological disorders** are treated. For the **London Insurance Market**, this breakthrough presents new opportunities and challenges in the field of pharmaceutical **risk management**. The ability to deliver drugs directly to the brain could lead to a reevaluation of **underwriting** practices and **risk assessments** for pharmaceutical companies. Insurers may need to consider the implications of such advanced treatments on **liability** and **product safety**. Additionally, the collaboration between CMUH, Ever Supreme Bio Technology, and Shine-On Biomedical underscores the importance of **international partnerships** in driving innovation, which could influence future **investment** and **insurance** strategies within the market.
For the London Insurance Market, this breakthrough presents new opportunities and challenges in the field of pharmaceutical risk management. The ability to deliver drugs directly to the brain could lead to a reevaluation of underwriting practices and risk assessments for pharmaceutical companies. Insurers may need to consider the implications of such advanced treatments on liability and product safety.